Clinical Trials Browser

Phase 1 × Recruiting × Hepatoblastoma × Clear all

Carcinoma, Hepatocellular, Liposarcoma, Liver Neoplasms, Wilms Tumor, Rhabdomyosarcoma, Hepatoblastoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT06198296 2025-11-03

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Phase 1 Recruiting

21 enrolled

GastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Liposarcoma, Wilms Tumor, Rhabdomyosarcoma, Hepatoblastoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT04897321 2025-10-24

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase 1 Recruiting

32 enrolled

CNSDermatologicGastrointestinalGenitourinarySarcoma

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04337177 2025-09-23

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Phase 1 Recruiting

20 enrolled

CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

Clinical Trials

IMPACT

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors